Table 4

Clinical characteristics of the DLBCL training cohort at diagnosis according to the MLH1 rs1799977 genotype

Clinical characteristicMLH1 rs1799977
P
AAAG/GG
Age > 60 y 71/111 (64.0%) 33/52 (63.5%) .950 
Male 59/111 (53.2%) 33/52 (63.5%) .216 
ECOG PS > 1 13/111 (11.7%) 8/52 (15.4%) .514 
Charlson Comorbidity Index 1 (0-2) 1 (0-3) .115 
Ann Arbor stage III or IV 56/111 (50.5%) 29/52 (55.8%) .526 
B symptoms 21/111 (18.9%) 17/52 (32.7%) .052 
Bulky 30/111 (27.0%) 16/52 (30.8%) .620 
Extranodal sites > 1 28/111 (25.2%) 13/52 (25.0%) .975 
LDH > ULN 33/111 (29.7%) 21/52 (40.4%) .177 
IPI 3-5 32/111 (28.8%) 17/52 (32.7%) .616 
Non-GC phenotype 35/79 (44.3%) 18/48 (37.5%) .450 
RDI of doxorubicin, % 94.8 (81.8-100) 88.2 (76.1-99.8) .123 
RDI of cyclophosphamide, % 95.8 (87.5-100) 92.1 (80.7-100) .236 
No. of R-CHOP courses 6 (6-8) 6 (4-8) .372 
1-year treatment-related mortality 1.8% 6.0% .286 
Clinical characteristicMLH1 rs1799977
P
AAAG/GG
Age > 60 y 71/111 (64.0%) 33/52 (63.5%) .950 
Male 59/111 (53.2%) 33/52 (63.5%) .216 
ECOG PS > 1 13/111 (11.7%) 8/52 (15.4%) .514 
Charlson Comorbidity Index 1 (0-2) 1 (0-3) .115 
Ann Arbor stage III or IV 56/111 (50.5%) 29/52 (55.8%) .526 
B symptoms 21/111 (18.9%) 17/52 (32.7%) .052 
Bulky 30/111 (27.0%) 16/52 (30.8%) .620 
Extranodal sites > 1 28/111 (25.2%) 13/52 (25.0%) .975 
LDH > ULN 33/111 (29.7%) 21/52 (40.4%) .177 
IPI 3-5 32/111 (28.8%) 17/52 (32.7%) .616 
Non-GC phenotype 35/79 (44.3%) 18/48 (37.5%) .450 
RDI of doxorubicin, % 94.8 (81.8-100) 88.2 (76.1-99.8) .123 
RDI of cyclophosphamide, % 95.8 (87.5-100) 92.1 (80.7-100) .236 
No. of R-CHOP courses 6 (6-8) 6 (4-8) .372 
1-year treatment-related mortality 1.8% 6.0% .286 

The 25th to 75th percentiles are reported in parentheses for continuous variables.

GC indicates germinal center.

or Create an Account

Close Modal
Close Modal